NovaHep enters into commercial license agreement with GemVax Technology Co., covering Korea, Japan and China
January 25, 2016
NovaHep has entered into a commercial license agreement with GemVax Technology Co. Ltd. (GemVax).
“We are very pleased with this agreement as it signifies a commercial validation of our technology and knowhow, with GemVax as a valuable partner for these important markets of ours”, says Dr. Petter Björquist, CEO of NovaHep AB.
In addition, the agreement entails know-how transfer related to NovaHep’s personalized tissue-engineered veins as basis for GemVax bringing them to market in Korea, Japan and China, leveraging on its expertise within development and commercialization.
“We greatly value NovaHep’s technology, which is truly unique. We are very happy with this agreement as we anticipate a vast potential with NovaHep’s tissue-engineered veins in Korea, Japan and China”, says Jay Kim, CEO of GemVax Technology Co., Ltd.
NovaHep continues to progress with its preparations for the upcoming Scandinavian clinical trial related to its personalized tissue-engineered vein with competent valves, targeting the disease Chronic Venous Insufficiency, in addition to its R&D activities within its promising pipeline of other tissue-engineered products.
For any questions related to this matter, please contact CEO Petter Björquist (+46 705 97 92 96).